ReNu Achieves Primary Endpoint in Phase 3 Trial for Knee Osteoarthritis

At 6 months, patients treated with ReNu exhibited significant reductions in assessed knee pain and maintained patient function compared with controls.

Related Keywords

United States ,Americans ,Adamb Yanke ,Patrick Bilbo ,Organogenesis Holdings Inc ,Drug Administration ,Holdings Inc ,Associate Professor ,Rush University Medical Center ,Co Principal Investigator ,Western Ontario ,Mcmaster Universities Arthritis Index ,Medicine Advance Therapy ,Chief Operating Officer ,Biologics License Application ,